SUMMARY Background
Refractory coeliac disease is a severe complication of coeliac disease with heterogeneous outcome.
Aim
To create a prognostic model to estimate survival of patients with refractory coeliac disease.
Methods
We evaluated predictors of 5-year mortality using Cox proportional hazards regression on subjects from a multinational registry. Bootstrap resampling was used to internally validate the individual factors and overall model performance. The mean of the estimated regression coefficients from 400 bootstrap models was used to derive a risk score for 5-year mortality.
Results
The multinational cohort was composed of 232 patients diagnosed with refractory coeliac disease across seven centres (range of 11-63 cases per centre). The median age was 53 years and 150 (64%) were women. A total of 51 subjects died during a 5-year follow-up (cumulative 5-year all-cause mortality = 30%). From a multiple variable Cox proportional hazards model, the following variables were significantly associated with 5-year mortality: age at refractory coeliac disease diagnosis (per 20 year increase, hazard ratio = 2.21; 95% confidence interval, CI: 1.38-3.55), abnormal intraepithelial lymphocytes (hazard ratio = 2.85; 95% CI: 1.22-6.62), and albumin (per 0.5 unit increase, hazard ratio = 0.72; 95% CI: 0.61-0.85). A simple weighted three-factor risk score was created to estimate 5-year survival.
Conclusions
Using data from a multinational registry and previously reported risk factors, we create a prognostic model to predict 5-year mortality among patients with refractory coeliac disease. This new model may help clinicians to guide treatment and follow-up. 1 Gluten-free diet is an effective therapy for most patients. 2 Diagnosed CD is associated with a modest increase in mortality, as well as certain types of cancer. [3] [4] [5] [6] [7] [8] Failure of expected symptomatic response to gluten-free diet may occur in some patients (5-30%). 9 Nonresponsive CD is defined by persistent or recurrent gastrointestinal symptoms despite apparent adherence to a gluten-free diet. 10 By far, inadvertent gluten contamination is the most common cause of nonresponsive CD. [10] [11] [12] Other causes of nonresponsive CD include microscopic colitis, exocrine pancreatic insufficiency, lactose intolerance, small intestine bacterial overgrowth, irritable bowel syndrome and refractory CD. 13 [20] [21] [22] This abnormal cell population can also be recognised by a clonally restricted rearrangement of the T-cell receptor gene by polymerase chain reaction. 15, [23] [24] [25] Response to treatment and overall prognosis are thought to be better for refractory CD type I as compared to refractory CD type II. 18, [26] [27] [28] Most patients with refractory CD type I respond well to steroids and/or immunosuppressives. [29] [30] [31] Conventional pharmacological therapies and more aggressive therapies such as single-agent chemotherapy, and stem-cell transplantation have been proposed for patients with the more severe refractory CD type II. 14, [32] [33] [34] [35] Prognosis of refractory CD type II is poor because therapies are less effective and high risk of progression to enteropathy-type T-cell lymphoma. 26, 28, 36 Besides the traditional classification of refractory CD, few other prognostic factors have been suggested. 28, 36 The a priori identification of subsets of patients with a higher risk of poor outcome may help to guide surveillance and therapeutic interventions. Unfortunately, a disease-specific prognostic model is lacking. Thus, there is a crucial need for a prognostic model to predict mortality among patients with refractory CD at the time of first presentation.
The purpose of the present study was to develop and validate a new model to predict survival in patients with refractory CD using a multinational cohort.
METHODS

Patients
The multinational refractory CD collaborative group consists of a network of seven centres (5 countries) collaborating for research on refractory CD. The multinational refractory CD registry is a retrospective cohort study established in 2009 to elucidate the outcome of refractory CD. The registry consists of patients diagnosed with refractory CD between July 1984, when the first patient was diagnosed, and December 2009, the cutoff date for entry into this report. Most patients (85%) were diagnosed after January 1999.
Diagnostic criteria for refractory CD
Conventional criteria for classification of the refractory CD (and types) were used to maximise the correct allocation of patients by categories. 9, 14, 15, 26, 28, 32, [36] [37] [38] The inclusion criteria included: (i) Persistence or recurrence of gastrointestinal symptoms (diarrhoea, involuntary loss of weight, and/or abdominal pain) and intestinal damage (at least partial villous atrophy) after gluten exclusion for at least 6 months. 39 Asymptomatic patients with persistent intestinal damage were not included as this may represent slow mucosal healing. 40 (ii) Evidence of dietary inquiry to exclude intentional or inadvertent gluten contamination. A negative coeliacspecific serology at the time of refractory CD diagnosis was not required but seems consistent with good compliance to gluten-free diet. 41 (iii) Need of alternative therapy because of lack of response to gluten-free diet alone. (iv) Absence of overt intestinal or systemic lymphoma at diagnosis of refractory CD. (v) Previous diagnosis of CD was supported by villous atrophy in small bowel biopsy and positive coeliac serology (tissue transglutaminase or endomysial antibody) and/or history of clinical response to the gluten-free diet. 42, 43 For the minority of patients without documented positive coeliac serology or clinical response to gluten-free diet, the diagnosis of refractory CD was supported by permissive human leucocyte antigen DQ2 and/or DQ8 and the exclusion of other known causes of enteropathy.
The presence of human leucocyte antigen alleles at-risk for CD DQ2 or DQ8, a family history of CD, and exclusion of other causes of enteropathy were considered supportive for the diagnosis of CD, especially in a minority of patients without either a positive coeliac serology and/ or history of clinical response to gluten-free diet [primary refractory CD]. 1, 38, 45, 46 Human leucocyte antigen DQ2
or DQ8 was not routinely required for CD diagnosis and when absent supported a high negative predictive value for CD diagnosis. 42, 43, 46 Accordingly, when patients were tested, the presence of human leucocyte antigen DQ2 and/or DQ8 was required for inclusion. Refractory CD type was determined by the absence (refractory CD type I) or presence (refractory CD type II) of an abnormal phenotype of intraepithelial lymphocyte determined by immunohistochemistry, flow cytometry, and/or T-cell clonality analyses.
Patients with 'prevalent' enteropathy-type T-cell lymphoma defined by lymphoma confirmation within 6 months of refractory CD diagnosis were excluded because the outcome is likely determined by the neoplasm but not by the refractory state itself. [47] [48] [49] [50] [51] Patients with other severe sprue-like conditions, such as adult autoimmune enteropathy, hypogammaglobulinemic sprue, collagenous sprue, drug-associated enteropathy and tropical sprue, were not included. [52] [53] [54] [55] [56] Data collection Clinical and laboratory data were collected from the medical record. Participant centres incorporated clinical information of their cases with refractory CD into a standardised electronic database as a common method for collection of information. At a coordinating centre (Mayo Clinic), control and supervision of all clinical data received was undertaken with communication with all participant centres for clarification (and resolution) of data inconsistencies. Additionally, endoscopy, imaging and pathology data were supplied by each centre. Histological findings were categorised using the modified Marsh classification. 57 Immunohistochemistry and T-cell clonality studies used to identify abnormal immunophenotype or clonal expansion of intraepithelial lymphocytes in the intestinal biopsy were included. 15, 20 At the time of data collection, flow cytometry was used routinely for assessment of refractory CD in few participant centres.
15, 22
Detection of clonal expansion of abnormal intraepithelial lymphocytes The presence of abnormal intraepithelial lymphocytes was evaluated in fixed or fresh frozen intestinal tissue by the following methods: (i) abnormal immunophenotype was defined by the lack of expression of the surface markers, CD3 and CD8, with preserved expression of the cytoplasmic CD3 (CD3e) in >50% of intraepithelial lymphocytes using immunohistochemistry or >20% using flow cytometry as previously described, 20, 22 and (ii) clonality studies by detection of T-cell receptor-c rearrangement by polymerase chain reaction or southern blot. 15, 23 It is not possible to differentiate between surface (CD3s) or cytoplasmic CD3 (CD3e) using immunohistochemistry; flow cytometry can overcome this limitation. 22 
Statistical analysis
Descriptive statistics on baseline variables are presented as median (range), mean (s.d.), or count (%) as appropriate. Seven a priori selected variables were evaluated as predictors of 5-year mortality with multiple variable Cox proportional hazards regression. Variables were selected based on prior single-centre reports of potential outcome implications in refractory CD. Preliminary analysis showed that the results from regression models pooling across all centres did not differ appreciably compared with those from models that stratified on centre and for brevity and ease of interpretability only the pooled results are reported. We assumed that data missingness occurred at random and used single imputation to predict unknown values of body mass index, albumin, haemoglobin and intraepithelial lymphocyte status (% missing ranged from 6% to 14%). A p-spline plot of the mortality hazard function against a smoothed version of each continuous variable was used to assess the adequacy of a linear relationship. Interactions between either age or intraepithelial lymphocyte status and other candidate risk factors were pre-specified as clinically meaningful and for both the corresponding group of interaction terms was simultaneously tested for significance (i.e. likelihood ratio test with 6 degrees of freedom) to avoid inflating type 1 error. All analyses were carried out with the statistical software package SAS, version 9.1 (SAS Institute, Cary, NC, USA), except for the p-spline plots which were done in R, version 2.13.0 (R Development Core Team, Vienna, Austria).
To internally validate the individual risk factors and overall model performance, bootstrap resampling was used. 58 For each of the 400 bootstrap resamples (selected via random sampling from the original set of patients, with replacement), we fit a multiple variable Cox proportional hazards model using the same seven predictors and obtained the survival concordance index (c-statistic)
as a measure of model performance. 59, 60 We then tested this bootstrap model on the original data and re-measured its performance. Bias was estimated as the average difference in c-statistic values between the bootstrap and test models, which was then subtracted from the 'apparent' measure (i.e. model c-statistic from original model fit) to obtain a bias-corrected concordance index. To visually assess calibration, which is the model's ability to accurately predict the absolute level of risk that is subsequently observed, deciles of predicted survival from the Cox proportional hazards model were plotted against the empirical survival rates obtained from the Kaplan-Meier method.
For each factor in the model, the average estimated regression coefficients from the 400 bootstrap resamples were used to weigh its contribution to the prediction score. The point value contribution to the prediction score for each factor, was calculated by dividing each coefficient by the minimum absolute value among all significant coefficients in the model (note some continuous variables were reparameterised to express their effect on a more meaningful scale), and then rounded to the nearest integer. A subject's risk score is simply the cumulative number of points from factor included in the model, with higher scores corresponding to increased risk of 5-year mortality.
To demonstrate that the simplified risk score adequately summarised the multiple variable model, a univariate Cox proportional hazards model with the risk score as the predictor variable was fit and its c-statistic was compared to that of the multiple variable model. In addition, the original multivariable model predicted 5-year survival estimates were plotted against corresponding estimates from the risk score model, and the agreement was assessed using Lin's concordance correlation coefficient. 61 
Ethical issues
This study was approved by the Institutional Review Boards of all participant centres.
RESULTS
Patients
A total of 21 subjects were excluded from the original cohort of 253 patients, 20 because of 'prevalent' enteropathy-type T-cell lymphoma (Paris, n = 5; Argentina, n = 4; New York, n = 4; Amsterdam, n = 3; Boston, n = 2; Rochester, n = 1; and Berlin, n = 1) and one because of no follow-up information (Boston, n = 1). In the final analysis set of 232 patients, median age was 53 years (range, 15-88 years), and 150 (64%) were women. The diagnosis of CD was supported by the presence of villous atrophy (212/212, 100%), including Marsh 3a 19 (8%), Marsh 3b 23 (11%), Marsh 3c 106 (50%), Marsh 3 no otherwise specified 64 (31%); at least one positive coeliac serology (IgA tissue transglutaminase or endomysial antibody) at the time of CD diagnosis (97/ 148, 66%); human leucocyte antigen DQ2 and/or DQ8 (158/158, 100%), and clinical response to gluten-free diet for a period of time before the refractory CD diagnosis (148/228, 65%). Moreover, 189/231 (82%) patients have had either documented positive coeliac serology (IgA tissue transglutaminase or endomysial antibody) or documented clinical response to gluten-free diet.
At the time of refractory CD diagnosis, immunohistochemistry was performed in 219 (94%) and positive in 111 (51%), T-cell receptor-c rearrangement test was performed in 185 (80%) and positive in 109 (60%), and flow cytometry was performed in 101 (43%) and positive in 62 (61%). Overall agreement between immunohistochemistry and flow cytometry was good (kappa 0.75; 95% confidence interval, CI 0.63-0.88) but only fair for both immunohistochemistry and flow cytometry with Tcell receptor-c rearrangement test (kappa 0.58; 95% CI 0.46-0.70 and 0.41; 95 CI 0.21-0.60 respectively). The median number of cases by participant centre was 28 (range, . Despite significant differences in several baseline characteristics across the seven participant centres, the rates of 5-year mortality did not differ significantly (P = 0.41). The 232 patients were followed from their date of refractory CD diagnosis until either death or last day of follow-up (median duration of 3.2 years; interquartile, 1.4-6.0 years). During a truncated follow-up period of 5 years, a total of 51 subjects died (Kaplan-Meier survival rate 70%) ( Table 1) . Refractory CD-related mortality was the most common cause of death (Table 2) .
Predictor variables
All study variables were evaluated as potential predictors of 5-year mortality using Cox proportional hazards regression. From p-spline plots, most of the continuous variables demonstrated a linear relationship with the hazard function and therefore were not transformed for the regression modelling. For haemoglobin, the relationship was generally linear except at its upper range when the hazard function sharply decreased, likely due to a paucity of high values in the cohort (the majority of subjects were below the normal range). To satisfy linearity, we transformed haemoglobin by capping values at the lower bounds of the normal range (14 g/dL for males and 12 g/dL for females). From a multiple variable model that included all seven hypothesised risk factors, increased age at diagnosis (P < 0.001), decreased albumin (P < 0.001) and abnormal intraepithelial lymphocyte (P = 0.015) were each significantly associated with 5-year mortality (model c-statistic = 0.750) ( Table 3) . To address the possibility of differential associations according to either age or intraepithelial lymphocyte status, we tested the corresponding group of interaction terms for significance but observed no overall differences in our model results (P = 0.73 and P = 0.07 from tests of group interactions for age and, separately, for intraepithelial lymphocyte with other candidate risk factors). As a sensitivity analysis, exclusion of nine patients with enteropathy-type T-cell lymphoma diagnosed within 12 months of refractory CD diagnosis resulted in no (45) 7 (32) 17 (32) 1 (6) 0 (0) 10 (28) 13 (36) appreciable differences in the model estimates or performance (c-statistic = 0.746).
Internal validation of regression modelling
To estimate the optimism bias in the original model fit and then compute a bias-corrected c-statistic, each bootstrap-selected model was tested against the original data and its performance was assessed. Compared to the apparent discrimination (c-statistic 0.750) of the multiple variable model, the bias-corrected c-statistic of 0.717 indicates a modest amount of optimism bias from the original model fit, though still a fair discriminative ability by the model. Furthermore, to assess calibration of the model, the 2-year predictions were divided into deciles, and the average predicted survival versus the empirical survival rates estimated by the Kaplan-Meier method were plotted ( Figure 1 ). As the identity line (or Y = X, which represents perfect calibration) falls within the 95% confidence limits of the empirical estimate for each decile, the model was deemed to be adequately calibrated.
Deriving the risk score
Two different versions of a prediction score were ultimately constructed and compared for estimating the risk of 5-year mortality in refractory CD patients. In the first version, a weighted point system was derived that used the regression coefficients but ignored the statistical significance of the factors (5-factor risk score). In the final multiple variable model, point values were assigned as the rescaled coefficient rounded to the nearest integer (note that a point value estimating to 0 ultimately means the factor is not incorporated into the scoring tool). Applying this algorithm, the first risk score assigned a variable number of points for the three significant factors depending on their values, and one point each for indication of male gender and total villous atrophy despite both not being significantly associated with the 5-year mortality (Table 4 ). In addition, a second risk score (3-factor risk score) was considered that incorporated only the point assignments for the three significant factors (identical to the original scoring except gender and villous atrophy are assigned no points), and compared its prognostic utility to that of the 5-factor risk score.
Relative to the apparent discrimination measured from the original multiple variable model (c-statistic = 0.750), both the 5-and 3-factor risk scores demonstrated fairly comparable measures of discrimination (c-statistic = 0.739 and 0.731 respectively). From scatterplots of predicted 5-year survival rates from the original multiple variable model plotted against those from each of the two risk score models, an excellent concordance in both and only marginal decrement in agreement from the simpler 3-factor risk score was observed (Lin's concordance correlation coefficient = 0.964 and 0.940 respectively, Figure 2) .
Furthermore, discrimination of the 3-factor risk score was illustrated by dividing the predictions in quartiles, and plotting the Kaplan-Meier curves of these four Figure 3 ).
DISCUSSION
We developed a prognostic model for refractory CD to predict 5-year mortality among patients with refractory CD. The 3-factor risk score requires simple clinical variables such as age at diagnosis of refractory CD, albumin in serum and immunophenotype of intraepithelial lymphocyte in a biopsy of the duodenum. Currently, the type of refractory CD based on the immunophenotype of intraepithelial lymphocyte is used to stratify patients into prognostic subgroups. 26, 28 Classification of refractory CD is based on the immunophenotype and clonality of intraepithelial lymphocyte of the small bowel. 15, 20, 22 We found good agreement between immunohistochemistry and flow cytometry but fair agreement between both immunohistochemistry and flow cytometry with T-cell receptor-c rearrangement. Testrelated performance limitations should be taken into account, when the immunophenotype of intraepithelial lymphocytes is used as single factor to predict the outcome in refractory CD. Although this classification may be useful to estimate the risk of progression to lymphoma (e.g. higher risk in refractory CD type II), 26, 28, 36 another limitation is that it tends to treat all patients the same regardless of presence of other risk factors such as age at diagnosis and/or albumin level. A major advantage of our proposed model is the use of commonly available clinical predictors (age, albumin and immunophenotype of intraepithelial lymphocytes) and thus the proposed model is easy to apply in everyday practice. This model was developed using a large and geographically dispersed group of patients suggesting it may be widely applicable. We anticipate continued improvement and refinement of the current model. The 3-factor risk score is preferable over the more complex 5-factor risk score because of its simplicity and similar discrimination power. A model with a c-statistic over 0.7 can be considered clinically useful, for example, the widely used MELD (model for end-stage liver disease) score has a c-statistic of 0.85. 62 Our 3-factor risk model c-statistic was 0.731. The present form of the model may be useful to counsel patients with refractory CD and might help clinicians to guide treatment decisions and/or follow-up. For example, individual patient survival probability at the time of refractory CD diagnosis can be used for risk stratification. A low score (0-7) with estimated 5-year Kaplan-Meier survival of 83-98% makes reasonable a more conservative treatment, whereas a high score (≥8) with estimated 5-year Kaplan-Meier survival of 48-61% may justify more intensive monitoring and increasingly aggressive interventions. In addition, the new model can be very useful to stratify patients according to prognosis at the time of enrolment in clinical trials for novel drugs for refractory CD. The proposed prognostic factors may lead to poor outcome by diverse mechanisms. Refractory CD-related mortality explained most deaths in our cohort. Abnormal intraepithelial lymphocytes have been extensively studied as risk factor for the development of enteropathy-type T-cell lymphoma. 15 Enteropathy-type T-cell lymphoma is associated with a poor prognosis despite therapy, although there is evidence of improvement in survival with a novel regimen of chemotherapy followed by autologous stem-cell transplantation. 26, 48, 51 Enteropathy-type T-cell lymphoma was the most frequent cause of death in our cohort explaining 35% of all deaths and seen almost exclusively in patients with abnormal intraepithelial lymphocytes. Targeted therapies that may decrease the risk of progression of refractory CD to enteropathy-type T-cell lymphoma are urgently needed. 33 Low serum albumin was a very strong negative prognostic factor in patients with refractory CD, although non-specific, it may be a measure of severity of disease, ongoing inflammation of the small bowel and/or malnutrition commonly associated with other frequent causes of death such as intestinal failure and severe infections. Vigorous nutritional support has been recommended and frequently used in patients with refractory CD. 14, 28, 36, 63 Low serum albumin has been reported as a negative prognostic factor in other diseases such as chronic liver disease (Child-Pugh score), myelodysplastic syndromes and patients on haemodialysis. [64] [65] [66] It is possible that other variables not included in the current model may increase robustness of the prognostic model in the near future (e.g. human leucocyte antigens, gene-expression profiles or 'molecular signatures' and/or proportion of aberrant cells by flow cytometry). 36 Indeed, the presence of ≥80% CD3e + CD3s À CD8 À intraepithelial lymphocytes by immunohistochemistry has been reported as a predictor of enteropathy-type T-cell lymphoma development in refractory CD. 25 Lymphomagenesis in refractory CD is a complex process and refinement of prognostic models towards individualised medicine will require a better understanding of the underlying molecular mechanisms. 67 Survival signals to intraepithelial lymphocytes in refractory CD require IL-15 and depend on the anti-apoptosis factor BcL-xL. 68 Different stages of maturity of intraepithelial lymphocytes in refractory CD may determine the size of the risk of progression to lymphoma and hence long-term prognosis.
69
A lineage-negative CD3s À CD7 + CD3e + CD127 À CD34 À IL-15 responsive subset of lymphocytes may represent the physiological counterpart of abnormal cells associated with refractory CD type II-associated lymphoma. 70 Study limitations include the retrospective nature of data and variable laboratory evaluation of patients across participant centres. However, clinical evidence for a prior diagnosis of CD was necessary for inclusion. Similar operational definition as well as exclusion criteria helped to mitigate heterogeneity. In fact, 5-year mortality rate was similar among participant centres and a pooled analysis was feasible and desirable. We did not use separate derivation and validation datasets due to rarity of refractory CD. Thus, prospective validation is advisable.
In conclusion, these data suggest that the new simplified 3-factor risk score that includes age, albumin and immunophenotype of intraepithelial lymphocytes is able to accurately predict 5-year mortality among patients with refractory coeliac disease. 
